Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by C10H12N2on Jun 11, 2022 11:29am

158 Views

Post# 34749235

Moreau misses/messaging/mark for the DMT stroke program.

Roth Capital Doubles Down on Cybin After DMT Acquisition

Earlier this week we reported on Cybin acquiring a DMT Clinical Study from Entheon Biomedical. The study is the largest Phase 1 DMT trial to date and should greatly accelerate Cybin’s CYB-004 DMT program.

And it seems like the financial world agrees on the potential benefits of this move, as Roth Capital has reiterated its Buy rating and bullish price target for Cybin. Based on this acquisition and strengthening of its DMT program, Roth has kept its $10 target, a sign of faith in the company’s programs especially considering the difficult market conditions.

https://microdose.buzz/news/elon-musk-tweets-psychedelics-with-cybin-ceo/

<< Previous

Bullboard Posts

Next >>

AI companies to invest in